scout

Authors

J. Leonard Lichtenfeld, MD
Latest Article

One Moment in Research

Recently, I was approached by one of my Texas colleagues and asked if I could help out with some legislation before the Texas state Senate. The bill (HJR90), which would authorize $3 billion for cancer prevention and research over the next 10 years, had passed the Texas House of Representatives, and was currently "in process" in the state Senate.

J. M. Vose
Latest Article

Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data

Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses

J. Milburn Jessup, MD
Latest Article

Pancreatic Cancer Surgical Practice Guidelines

The Society of Surgical Oncology surgical practice guidelines focus on the signs and symptoms of primary cancer, timely evaluation of the symptomatic patient, appropriate preoperative extent of disease evaluation, and role of the surgeon in

J. P. Farcet
Latest Article

Efficiency of In Vivo Purging With Rituximab Followed by High-Dose Therapy With Autologous Peripheral Blood Stem Cell Transplantation in B-Cell Non-Hodgkin’s Lymphomas: A Single-Institution Study

High-dose therapy (HDT) with peripheral blood stem cell transplantation is a treatment option for patients with advanced follicular, marginal, and mantle cell lymphoma. In this setting, frequent contamination of peripheral blood stem cell harvests by

J. P. Grapin, MD
Latest Article

European Experience With Irinotecan Plus Fluorouracil/Folinic Acid or Mitomycin

Tremendous progress has been made in the medical treatment of advanced colorectal cancer during the past 2 to 3 years, due to the availability of several new drugs. Of these new agents, irinotecan (CPT-11 [Camptosar]) seems

J. P. Leonard
Latest Article

Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data

Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses

J. Randolph Hecht, MD
Latest Article

Irinotecan and Paclitaxel in Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia

Both irinotecan (CPT-11, Camptosar) and paclitaxel have beenshown to have single-agent activity in adenocarcinomas of the esophagusand gastric cardia. A phase I trial of the combination at UCLAestablished the dose as irinotecan at 225 mg/m2 and paclitaxel at100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of thisregimen in adenocarcinomas of the gastroesophageal junction showgood tolerability and promising activity (response rate of 27%), even inA previously treated patients.

J. Robert Cassady, MD
Latest Article

Response of the Normal Eye to High Dose Radiotherapy

his excellent review analyzes ophthalmologic complications following high-dose irradiation of the orbit and surrounding structures as a necessary adjunct to the treatment of patients with carcinomas of the head and neck region. It confirms the critical importance of dose-fraction size in the production of radiation complications, especially in nerve tissue.

J. Ryan Mark, MD
Latest Article

Nonpalpable Intratesticular Mass in a Young Man With a History of Contralateral Retractile Testis

A 24-year-old otherwise healthy man with a history of retractile right testicle managed with right orchidopexy at age 9 presented with a several weeks’ history of discomfort in the left testicle. He has no family history of testicular cancer.

J. Sastre Valera, MD, PhD
Latest Article

Neoadjuvant Therapy With Cisplatin/Fluorouracil vs Cisplatin/UFT in Locally Advanced Squamous Cell Head and Neck Cancer

This study compared the activity and toxicity of fluorouracil (5-FU)/cisplatin with the combination tegafur and uracil (UFT)/cisplatin in the neoadjuvant treatment of locally advanced-stage III or IV (M0)-head and neck

J. Sybil Biermann, MD
Latest Article

Cancer Information on the Internet

This appendix highlights selected websites that are developed especially for oncology professionals, researchers, and patients with cancer.

J. T. Hickok, MD, MPH
Latest Article

Initial Control of Chemotherapy-Induced Nausea and Vomiting in Patient Quality of Life

The side effects commonly experienced by patients receiving chemotherapy for the treatment of cancer can challenge many aspects of daily life. Nausea and vomiting, the most common side effects reported by patients, affect the ability to continue with usual life activities and, thus have a pronounced impact on quality of life.

J. Tate Thigpen, MD
Latest Article

Treating Older Patients With Ovarian Cancer: Another Perspective

Dr. Piver presents a personal look at the issues he believes to be important in managing ovarian carcinoma in the elderly patient. He begins with an attempt to define elderly.

J. Troncy
Latest Article

Radiotherapy Versis Chemotherapy as ConsolidativeTreatment for Stage IIIB-IV Hodgkin’s Disease in First Complete Remission or Good Partial Response: A Study of 559 Patients (H89 Protocol)

The role of radiotherapy in combination with chemotherapy in advanced-stage Hodgkin’s disease remains controversial.

J. U. Rüffer
Latest Article

2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany

BACKGROUND: Extended-field radiotherapy is effective in patients with early-stage Hodgkin’s disease, and more than

J. William Charboneau, MD
Latest Article

Percutaneous Ablation: Safe, Effective Treatment of Bone Tumors

Percutaneous radiofrequency ablation (RFA) of osteoid osteomashas replaced surgical excision as the preferred method for treatment ofthese benign lesions, due to high effectiveness and low morbidity. BothRFA and cryoablation are safe and effective for palliation of pain dueto metastatic disease in patients who have failed conventional therapies.These image-guided treatments can be performed precisely, allowingsafe treatment of complex metastatic tumors. A single ablationtreatment is effective in most patients, is well tolerated, and provides along duration of pain relief.

J. William Harbour, MD
Latest Article

Uveal and Conjunctival Melanoma: Close Together-but Only Distantly Related

There has been rapid progress in the treatment of metastasis associated with cutaneous melanoma, including impressive results achieved with targeted molecular therapies and immunotherapies, and it is possible (but still unproven) that patients with metastasis from conjunctival and eyelid melanomas may benefit from these new therapies.

J. Wolf
Latest Article

2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany

BACKGROUND: Extended-field radiotherapy is effective in patients with early-stage Hodgkin’s disease, and more than

Jaafar Bennouna, MD
Latest Article

Update on European Adjuvant Trials With Irinotecan for Colorectal Cancer

Recent combinations of chemotherapy have significantly improved the response rate and survival time for patients with metastatic colorectal cancer.

Jacalyn Gano, RN
Latest Article

Counseling Women at High Risk of Ovarian or Endometrial Cancer

Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.

Jacek Pinski, MD, PhD
Latest Article

Advanced Prostate Cancer: New Agents, New Questions

Drs. Ruch and Hussain provide an excellent overview of the emerging therapeutic agents and targets for advanced prostate cancer.

Jack A. Roth, MD, FACS
Latest Article

Thoracic Metastases From Sarcoma: a Commentary

Surgical resection of isolated pulmonary metastases has been incorporated into the management of cancer for more than 70 years. However, many questions still remain concerning indications, technique, and efficacy for this approach.

Jack Basil, MD
Latest Article

Commentary (Basil): Management of Early Ovarian Cancer

Dr. Sonoda has provided a thoroughsummary of the managementof early-stage ovariancancer. He highlights the importanceof accurate and completesurgical staging of this disease entity.Laparoscopic staging is discussed asa potential alternative to the classicopen laparotomy staging procedure.In addition, the author includes anextensive review of trials discussingchemotherapy, radiation therapy, andintraperitoneal therapy as adjuvanttreatment for early-stage disease.

Jack L. Gluckman, MD
Latest Article

Management of Tumors of the Parapharyngeal Space

This paper offers a very good overview of a large topic that encompasses a multitude of tumors, each with its own set of controversial issues in terms of diagnosis and management. The authors discuss the various diagnostic and therapeutic options available for these tumors in a general sense, rather than concentrating on the specifics of each pathology. Although this approach certainly provides a satisfactory overview, it does not delineate the many diagnostic and therapeutic dilemmas that may confront the practicing head and neck surgeon. However, given the space limitations for such a paper, a more detailed discussion probably was infeasible.

Jack T. Fulmer, MD
Latest Article

Management of Locally Advanced Breast Cancer

Multimodality therapy-ie, surgical excision followed by appropriate systemic therapy and radiotherapy-has an established role in managing patients with locally

Jack W. Martin, MS
Latest Article

Minimizing Oral Complications of Cancer Treatment

Aggressive cancer therapy places patients at greater risk for oral complications and treatment-related consequences. Unfortunately, prevention and/or treatment of such oral sequelae have become often overlooked priorities of the treatment team.

Jack Yang, PhD
Latest Article

IMRT for Prostate Cancer Possible in Community Hospitals

An estimated 180,400 new prostate cancer cases will be diagnosed in the United States this year, and many of these patients will be diagnosed and treated at community cancer centers.

Jackie Baker, RN
Latest Article

Irinotecan/Cisplatin in Advanced, Treated Gastric or Gastroesophageal Junction Carcinoma

We conducted a phase II study to assess the response rate and toxicity profile of the irinotecan (CPT-11, Camptosar) plus cisplatin combination administered weekly to patients with at least one previous chemotherapy for advanced adenocarcinoma of the stomach or gastroesophageal junction. Patients with histologic proof of adenocarcinoma of the stomach or gastroesophageal junction with adequate liver, kidney, and bone marrow functions were treated with 50 mg/m² of irinotecan plus 30 mg/m² of cisplatin, both administered intravenously 1 day a week for 4 consecutive weeks, followed by a 2-week recovery period.

Jackie S. Fairweather, RN
Latest Article

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly

Jackson E. Fowler, Jr, MD
Latest Article

Prostate Cancer and African-American Men

The article by Powell highlights uncertainties about the relative contributions of diagnostic delay and tumor biology to racial disparities in stage at diagnosis among American men with prostate cancer, and explores a variety of factors that may discourage early cancer detection in African-American men. Observations derived from our ongoing prospective studies of prostate cancer diagnosis and treatment outcomes in black and white American veterans and from our experience with prostate cancer screening at the University of Mississippi Hospital and Clinics afford additional insights into these issues and provide a framework for this commentary.
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us